title: Novel therapies in MM: from the aspect of preclinical studies.
abstract: During the last decade, thalidomide, lenalidomide, and bortezomib have been approved by the US Food and Drug Administration for the treatment of MM; however, MM remains incurable. The development and progression of multiple myeloma (MM) is a complex multi-step process involving genetic abnormalities in tumor cells at both early and late stages. Moreover, soluble factors and cell-cell contact within the tumor bone marrow (BM) microenvironment promotes MM cell growth, survival, and drug resistance. A number of novel agents targeting both tumor cells and growth factors in the BM milieu have been developed. Currently they are under evaluation in preclinical studies, as single agents and/or in combination, to improve outcome of MM patients.
authors: Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA. teru_hideshima@dfci.harvard.edu.
authors: Teru
authors: T
authors: Hideshima
authors: Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.
authors: Kenneth C
authors: KC
authors: Anderson
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D060833:Cellular Microenvironment / Q000187:drug effects; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents